Table of Content

1. Introduction to Tropomyosin Receptor Kinase (TRK) Inhibitors
1.1 Overview to TRK Inhibitors
1.2 Evolution of TRK Inhibitors


2. TRK - Potential Target in Cancer Therapy


3. TRK Inhibitors Mechanism of Action


4. Global TRK Inhibitor Market Insight
4.1 Market Overview
4.2 Current Market Trends


5. TRK Inhibitors Market Regional Analysis
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World


6. TRK Inhibitors Market by Indication
6.1 Lung Cancer
6.2 Breast Cancer
6.3 Colorectal Cancer
6.4 Papillary Thyroid Cancer
6.5 Glioblastoma


7. Vitrakvi (Larotrectinib) – First Approved TRK Inhibitor
7.1 Overview
7.2 Patents & Assignees


8. Vitrakvi (Larotrectinib) – Commercial Information
8.1 Pricing
8.2 Sales Analysis


9. Rozlytrek (Entrectinib) – Second Approved TRK Inhibitor
9.1 Overview
9.2 Patents & Assignees


10. Rozlytrek (Entrectinib) – Commercial Information
10.1 Price & Dosage Anlaysis
10.2 Sales Analysis


11. TRK Inhibitors Sales Forecast 2026
11.1 Vitrakvi Sales Forecast
11.2 Rozlytrek Sales Forecast


12. Key TRK Inhibitors Drugs in Clinical Development
12.1 Selitrectinib
12.2 Repotrectinib
12.3 Taletrectinib
12.4 VMD928
12.5 ICP723
12.6 CHC2014


13. Global TRK Inhibitors Clinical Pipeline (By Drugs) Insight
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-III


14. Marketed TRK inhibitors Clinical Insight


15. Global TRK Inhibitors Clinical Pipeline (By Trials/Studies) Insight
15.1 By Phase
15.2 By Status
15.3 By Region


16. Global TRK Inhibitors Market Future Outlook


17. Global TRK Inhibitor Market Dynamics
17.1 Market Drivers
17.2 Market Challenges


18. Competitive Landscape
18.1 AstraZeneca
18.2 Aum Biosciences
18.3 Bayer
18.4 CMG Pharmaceutical
18.5 Eli Lilly & Company
18.6 InnoCare
18.7 Loxo Oncology
18.8 Ono Pharmaceutical
18.9 Pfizer
18.10 Roche
18.11 Turning Point Therapeutics